AstraZeneca PLC (LON: AZN)
London flag London · Delayed Price · Currency is GBP · Price in GBX
10,256
+12 (0.12%)
Dec 20, 2024, 7:05 PM BST

AstraZeneca Company Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.

The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.

It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target.

The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.

AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC
AstraZeneca logo
Country United Kingdom
Founded 1992
Industry Drug Manufacturers - General
Sector Healthcare
Employees 89,900
CEO Pascal Soriot

Contact Details

Address:
1 Francis Crick Avenue
Cambridge, CB2 0AA
United Kingdom
Phone 44 20 3749 5000
Website astrazeneca.com

Stock Details

Ticker Symbol AZN
Exchange London Stock Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number GB0009895292
SIC Code 2834

Key Executives

Name Position
Pascal Soriot D.V.M., M.B.A. Chief Executive Officer and Executive Director
Dr. Aradhana Sarin M.D. Chief Financial Officer and Executive Director
Pam P. Cheng Executive Vice President of Global opt. and IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Andrew P. Barnett Head of Investor Relations
Jeffrey Pott J.D. CHRO, Chief Compliance Officer, General Counsel and Member of External Sustainability Advisory Board
Gonzalo Vina Head of Global Media Relations
Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D., Ph.D. Executive Vice President of Oncology Research and Development
Iskra Reic Executive Vice President of International
David Fredrickson Executive Vice-President of Oncology Business Unit